Biotech Values

[ghmm]

Hmmm not the best symbol for a stock but I still like the company :). 86.25 million no way this is the full cap. Even a tiny penetration of Cerazyme should be worth a pretty penny. I have to do more research but I got the sense Genzyme's Pompe drug left a lot to be desired and that is one of the larger lysosomal diseases. Amicus is in Phase 1 but this could potential be a huge drug too! The Fabry drug is oral I believe which would be an advantage over TKT (Shire's) and Genzyme's but I don't know much about its efficacy.

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070330:MTFH67636_2...

WASHINGTON, March 30 (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. said on Friday it is planning an initial public offering of as much as $86.25 million in common stock.

Morgan Stanley, Merrill Lynch & Co., JPMorgan, Lazard Capital Markets and Pacific Growth Equities LLC, according to a preliminary offering document filed with the U.S. Securities and Exchange Commission.

It is seeking a Nasdaq listing under the symbol "FOLD."